Welcome to InfiCure Bio

InfiCure Bio is a life science company focusing on preclinical development and validation of drugs that target chronic inflammatory and fibrotic conditions.

Based on a panel of in vivo models for these conditions including a proprietary model for chronic inflammation and fibrosis, we offer effect tests of anti-inflammatory and anti-fibrotic drugs.

Founded on extensive experience and expertise in immunology, inflammation and fibrosis research, InfiCure Bio offers a proficient and flexible processing of drug validation projects in this area.

News

  • Vinnova

Innovative Start up Phase II grant

InfiCure Bio was awarded Innovative Start up Phase II from Vinnova. This opens up an additional market segment for InfiCure Bio, since the grant will fund the validation of the N-IF and the NFL strains as [...]

Anti-Fibrotic Drug Development Summit

InfiCure Bio is one of the sponsors of Anti-Fibrotic Drug Development Summit (AFDD) at Hyatt Regency in Boston. The AFDD brings together important experts in different areas of drug development with the aim to find better solutions [...]

  • Horizon 2020

Horizon 2020 SME application granted!

Our application to Horizon 2020 SME Phase I was granted! Read about our project in the Horizon 2020 SME Instrument data hub.    

Local investors believe in InfiCure Bio

PartnerInvest Norr and Nordic Light Capital are local investors investing in InfiCure Bio. This is a great opportunity for InfiCure which makes it possible for the company to go global and expand its business. Read [...]